Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 4, 2009, Pages 567-576

  Moake, Joel ^a  

^a Rice University   (United States)

Author keywords

ADAMTS 13; bevacizumab; cyclosporine; haemolytic uraemic syndrome; preeclampsia HELLP; tacrolimus; thrombotic microangiopathy; thrombotic thrombocytopenic purpura; von Willebrand factor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CALCINEURIN; CLOPIDOGREL; CYCLOSPORIN; ECULIZUMAB; GEMCITABINE; GLUCOCORTICOID; MITOMYCIN; MITOMYCIN C; QUININE; RITUXIMAB; SUNITINIB; TACROLIMUS; TICLOPIDINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTERY THROMBOSIS; BONE MARROW TRANSPLANTATION; CHEMOTHERAPY; DIARRHEA; DRUG MEGADOSE; ENZYME ACTIVITY; ERYTHROCYTE; HELLP SYNDROME; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIA; KIDNEY DYSFUNCTION; MEGAKARYOCYTE; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; WHOLE BODY RADIATION;

HEMOLYTIC-UREMIC SYNDROME; HUMANS; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 71749112406     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.07.004     Document Type: Review

References (45)

1. Moake J.L. Thrombotic microangiopathies. N Engl J Med 347 (2002) 589-600
2. Ruutu T., Barosi G., Benjamin R.J., et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 92 (2007) 95-100
3. Moake J.L. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. In: Michelson A.D. (Ed). Platelets (2006), Academic Press, Burlington, MA 903
4. Eremina V., Jefferson J.A., Kowalewska J., et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358 (2008) 1129-1136
5. Moake J.L., Rudy C.K., Troll J.H., et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307 (1982) 1432-1435
6. Furlan M., Robles R., Solenthaler M., et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 89 (1997) 3097-3103
7. Dong J.F., Moake J.L., Nolasco L., et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100 (2002) 4033-4039
8. Padilla A., Moake J.L., Bernardo A., et al. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood 103 (2004) 2150-2156
9. Moake J.L., Turner N.A., Stathopoulos N.A., et al. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 78 (1986) 1456-1461
10. Arya M., Anvari B., Romo G.M., et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood 99 (2002) 3971-3977
11. Moake J.L., Byrnes J.J., Troll J.H., et al. Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura. Blood 65 (1985) 1232-1236
12. Furlan M., Robles R., Galbusera M., et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339 (1998) 1578-1584
13. Tsai H.M., and Lian E.C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339 (1998) 1585-1594
14. Bernardo A., Ball C., Nolasco L., et al. Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. J Thromb Haemost 3 (2005) 562-570
15. Dong J.F., Moake J.L., Bernardo A., et al. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 278 (2003) 29633-29639
16. Turner N., Nolasco L., Dong J.F., et al. ADAMTS-13 cleaves long von Willebrand factor multimeric strings anchored to endothelial cells in the absence of flow, platelets or conformation-altering chemicals. J Thromb Haemost 7 (2009) 229-232
17. Turner N., Nolasco L., Tao Z., et al. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost 4 (2006) 1396-1404
18. Fujikawa K., Suzuki H., McMullen B., et al. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 98 (2001) 1662-1666
19. Levy G.G., Nichols W.C., Lian E.C., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413 (2001) 488-494
20. Zheng X., Chung D., Takayama T.K., et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276 (2001) 41059-41063
21. Bernardo A., Ball C., Nolasco L., et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 104 (2004) 100-106
22. Tao Z., Peng Y., Nolasco L., et al. Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions. Blood 106 (2005) 4139-4145
23. Bianchi V., Robles R., Alberio L., et al. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 100 (2002) 710-713
24. Tao Z., Anthony K., Peng Y., et al. Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura. J Thromb Haemost 4 (2006) 1931-1935
25. Tsai H.M., Rice L., Sarode R., et al. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 132 (2000) 794-799
26. Bennett C.L., Connors J.M., Carwile J.M., et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 342 (2000) 1773-1777
27. Zakarija A., Kwaan H.C., Moake J.L., et al. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl (2009) S20-S24
28. Pos W., Luken B.M., Hovinga J.A., et al. VH1-69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 7 (2009) 421-428
29. Luken B.M., Turenhout E.A., Hulstein J.J., et al. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 93 (2005) 267-274
30. Klaus C., Plaimauer B., Studt J.D., et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 103 (2004) 4514-4519
31. Mannucci P.M., Canciani M.T., Forza I., et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 98 (2001) 2730-2735
32. Kennedy A.S., Lewis Q.F., Scott J.G., et al. Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion (2009)
33. Plaimauer B., Zimmermann K., Volkel D., et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 100 (2002) 3626-3632
34. Gilbert J.C., Feo-Fraulini T., Hutabarat R.M., et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 116 (2007) 2678-2686
35. van der Plas R.M., Schiphorst M.E., Huizinga E.G., et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 93 (1999) 3798-3802
36. Karmali M.A., Petric M., Lim C., et al. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 151 (1985) 775-782
37. Nolasco L.H., Turner N.A., Bernardo A., et al. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood 106 (2005) 4199-4209
38. Warwicker P., Goodship T.H., Donne R.L., et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 53 (1998) 836-844
39. Bonnardeaux A., and Pichette V. Complement dysregulation in haemolytic uraemic syndrome. Lancet 362 (2003) 1514-1515
40. Fremeaux-Bacchi V., Dragon-Durey M.A., Blouin J., et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 41 (2004) e84
41. Moake J.L., and Byrnes J.J. Thrombotic microangiopathies associated with drugs and bone marrow transplantation. Hematol Oncol Clin North Am 10 (1996) 485-497
42. Nolasco L.H., Gushiken F.C., Turner N.A., et al. Protein phosphatase 2B inhibition promotes the secretion of von Willebrand factor from endothelial cells. J Thromb Haemost (2009)
43. Ono T., Mimuro J., Madoiwa S., et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 107 (2006) 528-534
44. Bollee G., Patey N., Cazajous G., et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 24 (2009) 682-685
45. Mutter W.P., and Karumanchi S.A. Molecular mechanisms of preeclampsia. Microvasc Res 75 (2008) 1-8